Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2024 | The role of TP53 & ctDNA kinetics in patients with R/R LBCL treated with glofitamab monotherapy

Carmelo Carlo-Stella • 21 Jun 2024

EHA 2024

B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Glofitamab

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, shares insights into the role of TP53 and circulating tumor DNA (ctDNA) kinetics in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) treated with glofitamab monotherapy. He notes that 25% of patients with TP53 mutations achieved complete remission (CR), and lower ctDNA levels were associated with improved outcomes. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Important practical considerations for the use of glofitamab for DLBCL

Carmelo Carlo-Stella • 20 Oct 2023

Glofitamab in R/R DLBCL: updated safety and efficacy data

Carmelo Carlo-Stella • 20 Oct 2023

Efficacy and safety of glofitamab for patients with Richter’s transformation

Carmelo Carlo-Stella • 15 Jun 2023

Glofitamab as a single agent in heavily pretreated patients with DLBCL

Carmelo Carlo-Stella • 15 Jun 2023

Related Videos

The sensitization of immune checkpoint inhibitors with subsequent chemotherapy in R/R HL

Jan Maciej Zaucha • 16 Jun 2024

The use of targeted drug therapy for aggressive lymphoma

Mariana Bastos • 14 Jun 2024

Reducing CRS following epcoritamab in R/R FL: insights from an optimization cohort of EPCORE NHL-1

Umberto Vitolo • 15 Jun 2024

Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia

Ramon Garcia-Sanz • 16 Jun 2024